scholarly journals Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection

2016 ◽  
Vol 3 (1) ◽  
pp. 58-69
Author(s):  
Pejman Solaimani ◽  
Christopher Hogan ◽  
Matthew Chin ◽  
Juan L Miranda ◽  
Douglas L Nguyen
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
The United States ◽  
Hepatitis C Infection ◽  
Pegylated Interferon Alpha ◽  
Emerging Therapies ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

With 5.2 million people living with Hepatitis C, it is the most common blood-borne infection in the United States. Untreated chronic HCV infection may result in adverse consequences such as cirrhosis, portal hypertension, hepatic failure and hepatocellular carcinoma. Previously approved treatments include Pegylated-interferon alpha-2a/2b plus ribavirin, Boceprevir and Telaprevir. Recently approved medications include Sofosbuvir (SOF), Simeprevir (SMV), Ledispavir-Sofosbuvir (Harvoni®) and Ombitasvir-paritaprevir-ritonavir with dasabuvir tablets (Viekira Pak). Here we review the literature describing the current and emerging therapies for chronic hepatitis C.

scholarly journals Is Being a Prisoner, Indigenous or Having a Psychiatric Illness an Acceptable Limitation to Treatment Access for Chronic Hepatitis C Infection?

2021 ◽  
Vol 5 (2) ◽  
pp. 01-03
Author(s):  
James Elliott ◽  
Gaffney L.
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection ◽  
Treatment Access ◽  
Decompensated Liver Cirrhosis ◽  
Treatment Regimens ◽  
Treatment Uptake ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

170 million people worldwide are infected with chronic hepatitis c virus (HCV) [1]. There are an estimated 226700 people infected in Australia and it is the most common indication for liver transplantation in this country [2]. Despite this, overall treatment uptake remains low at <2% of patients infected undergoing treatment per year [3]. Rates of admission to hospital with decompensated liver cirrhosis are expected to increase by 190% by 2030 [4]. Cure of chronic HCV infection requires complex treatment regimens for several months.

scholarly journals Blood markers of endothelial dysfunction and their correlation to cerebrovascular reactivity in patients with chronic hepatitis C infection

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e10723
Author(s):  
Mirela Pavicic Ivelja ◽  
Kresimir Dolic ◽  
Leida Tandara ◽  
Nikola Perkovic ◽  
Antonio Mestrovic ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Endothelial Dysfunction ◽  
Chronic Hepatitis C ◽  
Cerebrovascular Reactivity ◽  
Control Group ◽  
Hepatitis C Infection ◽  
Endothelial Markers ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Although liver cirrhosis and hepatocellular carcinoma are major consequences of hepatitis C (HCV), there has been an increasing number of studies examining extrahepatic manifestations, especially those caused by systemic chronic inflammation and metabolic complications that might predispose HCV patients to atherosclerosis and ischemic cerebrovascular disease (CVD). The aim of our study was to assess E-selectin, VCAM-1, ICAM-1 and VEGF-A serum levels in patients with chronic HCV infection and to correlate them with cerebrovascular reactivity. A blood sample was taken from eighteen patients with chronic hepatitis C infection and from the same number of healthy blood donors in the control group. The aim was to analyse markers of endothelial dysfunction and to correlate them with cerebrovascular reactivity expressed as breath-holding index (BHI) determined using transcranial color Doppler. The obtained results revealed significant differences between the groups in all endothelial markers except for the E selectin. While the ICAM-1 and sVCAM-1 were significantly increased in the hepatitis group, VEGF-A was significantly decreased. A significant reduction of 0.5 (95% CI 0.2, 0.8) in the mean BHI was found in the hepatitis group (mean BHI 0.64) compared to controls (mean BHI 1.10). No significant association between the BHI and any of the endothelial markers was found in the control group, while in the hepatitis group, the scatter plot of ICAM-1 vs BHI suggested that the association might be present. In conclusion, the results of this study confirm an association between a chronic HCV infection and altered cerebrovascular reactivity as well as higher levels of markers of endothelial activation (ICAM-1, VCAM-1) as possible indicators of an increased CVD risk.

scholarly journals Prediction of Effect of Pegylated Interferon Alpha-2b plus Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Infection

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e27223 ◽  
Author(s):  
Tetsuro Takayama ◽  
Hirotoshi Ebinuma ◽  
Shinichiro Tada ◽  
Yoshiyuki Yamagishi ◽  
Kanji Wakabayashi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Hepatitis C Infection ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha 2B
Sign in / Sign up

Export Citation Format

Share Document